Phase 1 Trial of the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Clinical Activity of RP-1664 in Participants with Advanced Solid Tumors
Study of RP-1664 in Patients with Solid Tumors
Sponsor: Repare Therapeutics
Enrolling: Male and Female Patients
IRB Number: AAAU9937
U.S. Govt. ID: NCT06232408
Contact: Research Nurse Navigator: 212-342-5162 /
Additional Study Information: The purpose of this study is to learn how well RP-1664 alone works to treat advanced solid tumor. RP-1664 has not been approved by the Food and Drug Administration (FDA). RP-1664 has not been given to humans prior to this study. Cancers include: bladder cancer, breast cancer, colon and rectal cancer, esophageal cancer, gynecologic cancers, head and neck/oral cancer, kidney cancer, liver cancer, lung cancer, skin cancer, pancreatic cancer, prostate cancer, stomach cancer, testicular cancer, and thyroid cancer.
Benjamin Herzberg, MD
Do You Qualify?
Are you at least 18 years old? Yes No
Are you able to swallow study drug? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator